A bittersweet moment as the industry congratulates our longtime colleague and collaborator, Nick Green, on a well-deserved retirement.
A bittersweet moment as the industry congratulates our longtime colleague and collaborator, Nick Green, on a well-deserved retirement.
It was a pleasure to visit such a well-run GLP lab at FairJourney Biologics’ headquarters in Porto, Portugal.
A fascinating presentation from Dr. Hollanbaugh, highlighting the discussion around Interleukin-2 (IL-2) inhibitors, which have emerged as a pivotal class of therapeutic agents, particularly in the realm of immunology and oncology.
Day Two of TAS25 kicks off with a presentation by Professor Madelon Maurice from the Madelon Maurice Lab in Holland.
Peter Senter, Ph.D., Janine Schuurman, Ph.D., and Greg Thurber, Ph.D. — now that’s a lineup.
Peter Senter, Ph.D., is the keynote for TAS25. Peter joined Seattle Genetics in 1998 and was part of the research team focused on anticancer therapies before the company’s $43 billion sale to Pfizer in 2023.
So grateful to the team at FairJourney Biologics for inviting our team to TAS25, their high-science discovery show in Porto, Portugal.
That’s Nice is visiting the FairJourney Biologics facilities in Porto, Portugal, as a kick-off to TAS2025: The Anti-Body Series.
Exciting to be able to check out the expanded construction at IDT’s facility in Germany.
A sneak peek at our first BIO interview: Mr. Mark Womack, CEO of BioCina.